Early pharmacokinetics of low dosage mycophenolate exposure in Thai kidney transplant recipients

被引:0
|
作者
Busaya Kulabusaya
Somratai Vadcharavivad
Yingyos Avihingsanon
Teun van Gelder
Kearkiat Praditpornsilpa
机构
[1] Chulalongkorn University,Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences
[2] Siriraj Hospital,Pharmacy Department
[3] Chulalongkorn University,Department of Medicine, Renal Immunology and Therapeutic Apheresis Research Unit, Faculty of Medicine
[4] Erasmus Medical Center,Department of Hospital Pharmacy
[5] Erasmus Medical Center,Department of Internal Medicine
[6] Chulalongkorn University,Department of Medicine, Faculty of Medicine
关键词
Kidney transplantation; Mycophenolate mofetil; Mycophenolic acid; Pharmacokinetics; Renal function;
D O I
暂无
中图分类号
学科分类号
摘要
Background The effects of mycophenolic acid exposure in the early period after transplantation on clinical outcomes have been reported; however, mycophenolic acid exposure in the early period after transplantation in Asian kidney transplant recipients who receive 1.5 g/d mycophenolate mofetil has never been investigated. Objective To determine mycophenolic acid exposure on day 3 post-transplantation in kidney transplant recipiens who receive 1.5 g/d mycophenolate mofetil. The effects of the reduced renal function on mycophenolic acid area under the concentration–time curve (AUC) and the achievement of the target AUC on the incidence of biopsy proven acute rejection during the first month post-transplantation were also evaluated. Setting A university hospital Method Blood samples and 24-h urine were collected on day 3 post-transplantation. Main outcome measures The mycophenolic acid AUC was calculated by linear trapezoidal rule and compared with the target of 45 mg*h/L. Results Of 42 Thai kidney transplant recipiens, the mean mycophenolic acid AUC of 45.1 mg*h/L (SD 14.7) was comparable to the AUC target (P = 0.962). Significant differences of the mycophenolic acid AUC were observed between patients with urine output of < 2400 mL and those with urine output ≥ 2400 mL (35.3 ± 6.6 and 47.4 ± 15.2, respectively; P = 0.002), and between patients with 24-h measured CrCl < 25 mL/min and those with CrCl ≥ 25 mL/min (38.0 (29.0, 42.2) and 49.2 ± 14.0, respectively; P = 0.017). Proportions of overall biopsy proven acute rejection among patients with mycophenolic acid AUC of < 45 and ≥ 45 mg*h/L were comparable (20.0% and 23.5%, respectively; P = 1.000). Conclusions After the starting dosage of 1.5 g/d mycophenolate mofetil, the mean mycophenolic acid AUC on day 3 post-kidney transplantation is comparable with the target of 45 mg*h/L. Severely reduced renal function significantly influences mycophenolic acid exposure.
引用
收藏
页码:1047 / 1055
页数:8
相关论文
共 50 条
  • [1] Early pharmacokinetics of low dosage mycophenolate exposure in Thai kidney transplant recipients
    Kulabusaya, Busaya
    Vadcharavivad, Somratai
    Avihingsanon, Yingyos
    van Gelder, Teun
    Praditpornsilpa, Kearkiat
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2019, 41 (04) : 1047 - 1055
  • [2] The pharmacokinetics of mycophenolate mofetil in Thai kidney transplant recipients
    Jirasiritham, S
    Sumethkul, V
    Mavichak, V
    Na-Bangchang, K
    [J]. TRANSPLANTATION PROCEEDINGS, 2004, 36 (07) : 2076 - 2078
  • [3] The impact of omeprazole on mycophenolate pharmacokinetics in kidney transplant recipients
    AbdElhalim, Mohamed S.
    Kenawy, Ahmed S.
    El Demellawy, Heba H.
    Azouz, Amany A.
    Alghanem, Sarah S.
    Al-Otaibi, Torki
    Gheith, Osama
    Abd ElMonem, Mohamed
    Afifi, Mohammed K.
    Hussein, Raghda R. S.
    [J]. KIDNEY RESEARCH AND CLINICAL PRACTICE, 2020, 39 (04) : 479 - 486
  • [4] Pharmacokinetics of Mycophenolate Mofetil and Development of Limited Sampling Strategy in Early Kidney Transplant Recipients
    Zhang, Jun
    Sun, Zhi
    Zhu, Zhenfeng
    Yang, Jing
    Kang, Jian
    Feng, Guiwen
    Zhou, Lin
    Zuo, Lihua
    Luo, Yonggang
    Zhang, Xiaojian
    [J]. FRONTIERS IN PHARMACOLOGY, 2018, 9
  • [5] Cyclosporin changes the pharmacokinetics of mycophenolate mofetil in kidney transplant recipients.
    Gregoor, PJHS
    Hesse, CJ
    van der Mast, BJ
    IJzermans, JNM
    Weimar, W
    van Gelder, T
    [J]. KIDNEY INTERNATIONAL, 1999, 55 (03) : 1164 - 1164
  • [6] Explaining Variability in Tacrolimus Pharmacokinetics to Optimize Early Exposure in Adult Kidney Transplant Recipients
    Press, Rogier R.
    Ploeger, Bart A.
    den Hartigh, Jan
    van der Straaten, Tahar
    van Pelt, Johannes
    Danhof, Meindert
    de Fijter, Johan W.
    Guchelaar, Henk-Jan
    [J]. THERAPEUTIC DRUG MONITORING, 2009, 31 (02) : 187 - 197
  • [7] Pharmacokinetics of mycophenolate sodium and comparison with the mofetil transplant recipients formulation in stable kidney
    Cattaneo, Dario
    Cortinovis, Monica
    Baldelli, Sara
    Bitto, Alessandra
    Gotti, Eliana
    Remuzzi, Giuseppe
    Perico, Norberto
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2007, 2 (06): : 1147 - 1155
  • [8] Pharmacokinetics of mycophenolate sodium and comparison with the mofetil formulation in stable kidney transplant recipients
    Cattaneo, Dario
    Baldelli, Sara
    Cortinovis, Monica
    Perico, Norberto
    Gotti, Eliana
    Remuzzi, Giuseppe
    [J]. THERAPEUTIC DRUG MONITORING, 2007, 29 (04) : 472 - 473
  • [9] THE IMPACT OF PROTON PUMP INHIBITORS (PPIS) ON MYCOPHENOLATE PHARMACOKINETICS IN KIDNEY TRANSPLANT RECIPIENTS
    Abd ElHalim, Mohamed
    Kenawy, Ahmed S.
    Gheith, Osama
    Abd El Monem, Mohamed
    Alghanim, Sara
    Mahmoud, Heba
    Azouz, Amany
    Sayed, Raghda
    Al-Otaibi, Torki
    Afifi, Mohamed K.
    [J]. TRANSPLANT INTERNATIONAL, 2019, 32 : 417 - 417
  • [10] Pregnancy Outcomes Related to Mycophenolate Exposure in Female Kidney Transplant Recipients
    King, R. W.
    Baca, M. J.
    Armenti, V. T.
    Kaplan, B.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 (01) : 151 - 160